ARTICLE | Company News
BioLeap LLC, GlaxoSmithKline deal
September 14, 2009 7:00 AM UTC
BioLeap will use its computational fragment-based drug design technology to develop compounds against undisclosed targets for GlaxoSmithKline. Further terms were not disclosed. ...